CEO
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry
BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey
BeiGene, biologics, innovation center, New Jersey, deals, CEO, John Oyler
MEI Pharma’s Leadership Shakeup: CEO and Medical Head Step Down Amidst Wind-Down Considerations
MEI Pharma, wind down, CEO, medical head, strategic alternatives
Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation
Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition
Exscientia, AI Biotech Firm, Announces Workforce Reduction Amidst Pipeline Changes and CEO Departure
Exscientia, AI biotech, workforce reduction, pipeline cut, CEO firing, restructuring, pharmaceutical industry, drug discovery
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.
UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm
UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.
AstraZeneca CEO Pascal Soriot’s Pay Rise Signals Succession Planning
AstraZeneca, Pascal Soriot, CEO, pay rise, succession planning, pharmaceutical industry, executive compensation.
23andMe Stock Surges as CEO Considers Taking Company Private
23andMe, Stock Jump, CEO, Privatization Plans, Genetics Company
Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies
Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross